Short Interest in UCB SA (OTCMKTS:UCBJY) Expands By 2,250.0%

UCB SA (OTCMKTS:UCBJY) was the recipient of a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 4,700 shares, an increase of 2,250.0% from the December 31st total of 200 shares. Based on an average daily trading volume, of 13,700 shares, the short-interest ratio is currently 0.3 days.

UCB Price Performance

UCBJY traded up $0.66 during trading on Wednesday, reaching $98.88. 5,757 shares of the company’s stock were exchanged, compared to its average volume of 7,263. The company’s fifty day simple moving average is $97.18 and its 200-day simple moving average is $92.14. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19. UCB has a 1 year low of $46.00 and a 1 year high of $100.66.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.